These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 23063513)

  • 1. A C-terminally amidated analogue of ShK is a potent and selective blocker of the voltage-gated potassium channel Kv1.3.
    Pennington MW; Harunur Rashid M; Tajhya RB; Beeton C; Kuyucak S; Norton RS
    FEBS Lett; 2012 Nov; 586(22):3996-4001. PubMed ID: 23063513
    [TBL] [Abstract][Full Text] [Related]  

  • 2. N-Terminally extended analogues of the K⁺ channel toxin from Stichodactyla helianthus as potent and selective blockers of the voltage-gated potassium channel Kv1.3.
    Chang SC; Huq R; Chhabra S; Beeton C; Pennington MW; Smith BJ; Norton RS
    FEBS J; 2015 Jun; 282(12):2247-59. PubMed ID: 25864722
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural conservation of the pores of calcium-activated and voltage-gated potassium channels determined by a sea anemone toxin.
    Rauer H; Pennington M; Cahalan M; Chandy KG
    J Biol Chem; 1999 Jul; 274(31):21885-92. PubMed ID: 10419508
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Affinity and selectivity of ShK toxin for the Kv1 potassium channels from free energy simulations.
    Rashid MH; Kuyucak S
    J Phys Chem B; 2012 Apr; 116(16):4812-22. PubMed ID: 22480371
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interaction of the Inhibitory Peptides ShK and HmK with the Voltage-Gated Potassium Channel K
    Sanches K; Prypoten V; Chandy KG; Chalmers DK; Norton RS
    J Chem Inf Model; 2023 May; 63(10):3043-3053. PubMed ID: 37143234
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of disulfide bonds in the structure and potassium channel blocking activity of ShK toxin.
    Pennington MW; Lanigan MD; Kalman K; Mahnir VM; Rauer H; McVaugh CT; Behm D; Donaldson D; Chandy KG; Kem WR; Norton RS
    Biochemistry; 1999 Nov; 38(44):14549-58. PubMed ID: 10545177
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Designed peptide analogues of the potassium channel blocker ShK toxin.
    Lanigan MD; Pennington MW; Lefievre Y; Rauer H; Norton RS
    Biochemistry; 2001 Dec; 40(51):15528-37. PubMed ID: 11747428
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutating a critical lysine in ShK toxin alters its binding configuration in the pore-vestibule region of the voltage-gated potassium channel, Kv1.3.
    Lanigan MD; Kalman K; Lefievre Y; Pennington MW; Chandy KG; Norton RS
    Biochemistry; 2002 Oct; 41(40):11963-71. PubMed ID: 12356296
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular mechanism of the sea anemone toxin ShK recognizing the Kv1.3 channel explored by docking and molecular dynamic simulations.
    Jin L; Wu Y
    J Chem Inf Model; 2007; 47(5):1967-72. PubMed ID: 17718553
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conformational exchange in the potassium channel blocker ShK.
    Iwakawa N; Baxter NJ; Wai DCC; Fowler NJ; Morales RAV; Sugase K; Norton RS; Williamson MP
    Sci Rep; 2019 Dec; 9(1):19307. PubMed ID: 31848433
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression and isotopic labelling of the potassium channel blocker ShK toxin as a thioredoxin fusion protein in bacteria.
    Chang SC; Galea CA; Leung EW; Tajhya RB; Beeton C; Pennington MW; Norton RS
    Toxicon; 2012 Oct; 60(5):840-50. PubMed ID: 22659540
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A potent and selective peptide blocker of the Kv1.3 channel: prediction from free-energy simulations and experimental confirmation.
    Rashid MH; Heinzelmann G; Huq R; Tajhya RB; Chang SC; Chhabra S; Pennington MW; Beeton C; Norton RS; Kuyucak S
    PLoS One; 2013; 8(11):e78712. PubMed ID: 24244345
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective blockade of T lymphocyte K(+) channels ameliorates experimental autoimmune encephalomyelitis, a model for multiple sclerosis.
    Beeton C; Wulff H; Barbaria J; Clot-Faybesse O; Pennington M; Bernard D; Cahalan MD; Chandy KG; Béraud E
    Proc Natl Acad Sci U S A; 2001 Nov; 98(24):13942-7. PubMed ID: 11717451
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A potent and Kv1.3-selective analogue of the scorpion toxin HsTX1 as a potential therapeutic for autoimmune diseases.
    Rashid MH; Huq R; Tanner MR; Chhabra S; Khoo KK; Estrada R; Dhawan V; Chauhan S; Pennington MW; Beeton C; Kuyucak S; Norton RS
    Sci Rep; 2014 Mar; 4():4509. PubMed ID: 24676092
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The D-diastereomer of ShK toxin selectively blocks voltage-gated K+ channels and inhibits T lymphocyte proliferation.
    Beeton C; Smith BJ; Sabo JK; Crossley G; Nugent D; Khaytin I; Chi V; Chandy KG; Pennington MW; Norton RS
    J Biol Chem; 2008 Jan; 283(2):988-97. PubMed ID: 17984097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analogs of the sea anemone potassium channel blocker ShK for the treatment of autoimmune diseases.
    Beeton C; Pennington MW; Norton RS
    Inflamm Allergy Drug Targets; 2011 Oct; 10(5):313-21. PubMed ID: 21824083
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Free energy simulations of binding of HsTx1 toxin to Kv1 potassium channels: the basis of Kv1.3/Kv1.1 selectivity.
    Rashid MH; Kuyucak S
    J Phys Chem B; 2014 Jan; 118(3):707-16. PubMed ID: 24397610
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting effector memory T cells with a selective peptide inhibitor of Kv1.3 channels for therapy of autoimmune diseases.
    Beeton C; Pennington MW; Wulff H; Singh S; Nugent D; Crossley G; Khaytin I; Calabresi PA; Chen CY; Gutman GA; Chandy KG
    Mol Pharmacol; 2005 Apr; 67(4):1369-81. PubMed ID: 15665253
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A three-residue, continuous binding epitope peptidomimetic of ShK toxin as a Kv1.3 inhibitor.
    Harvey AJ; Gable RW; Baell JB
    Bioorg Med Chem Lett; 2005 Jul; 15(13):3193-6. PubMed ID: 15935664
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potassium channel blockade by the sea anemone toxin ShK for the treatment of multiple sclerosis and other autoimmune diseases.
    Norton RS; Pennington MW; Wulff H
    Curr Med Chem; 2004 Dec; 11(23):3041-52. PubMed ID: 15578998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.